The stock of Arch Biopartners Inc (CVE:ACH) is a huge mover today! About 24,000 shares traded hands or 88.87% up from the average. Arch Biopartners Inc (CVE:ACH) has risen 6.00% since October 4, 2016 and is uptrending. It has outperformed by 4.79% the S&P500.
The move comes after 6 months positive chart setup for the $27.71M company. It was reported on Nov, 3 by Barchart.com. We have $1.04 PT which if reached, will make CVE:ACH worth $29.65M more.
More recent Arch Biopartners Inc (CVE:ACH) news were published by: Marketwired.com which released: “Arch Biopartners Appoints Adrian Haigh to Board of Directors” on August 21, 2014. Also Marketwired.com published the news titled: “Arch Biopartners Receives Orphan Drug Designation from FDA for AB569” on November 13, 2015. Marketwired.com‘s news article titled: “Arch Biopartners Retains Virtus Advisory to Provide Investor Relations Services” with publication date: October 21, 2015 was also an interesting one.
Arch Biopartners Inc. is a portfolio biotechnology company. The company has a market cap of $27.71 million. The Firm is focused on the development of technologies. It currently has negative earnings. The Company’s technologies include AB569, MetaMx, MetaBlok, Borg and Arch Inflammation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.